Alpelisib
A targeted cancer therapy that blocks PI3K-alpha, a specific enzyme that is often overactive due to PIK3CA gene mutations and drives the growth of certain breast, colorectal, and bladder cancers. By interrupting this signaling pathway, alpelisib can slow tumor growth, particularly in hormone receptor-positive, HER2-negative breast cancer.
Masse moléculaire
441,5000 g/mol
LogP
3,20
TPSA
129,00 Ų
Règle des 5 de Lipinski
Conforme
Aires thérapeutiques
Mécanisme d'action
Targets the HER2 (ErbB2) receptor tyrosine kinase, blocking HER2-mediated signaling that drives proliferation in HER2-overexpressing cancer cells.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Targets the HER2 (ErbB2) receptor tyrosine kinase, blocking HER2-mediated signaling that drives proliferation in HER2-overexpressing cancer cells.
Structure 2D
Cite this structure
Embed this structure
SMILES
Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1ccnc(C(C)(C)C(F)(F)F)c1
InChI
InChI=1S/C19H22F3N5O2S/c1-10-14(11-6-7-24-13(9-11)18(2,3)19(20,21)22)30-16(25-10)26-17(29)27-8-4-5-12(27)15(23)28/h6-7,9,12H,4-5,8H2,1-3H3,(H2,23,28)(H,25,26,29)/t12-/m0/s1
Molecular Formula
C19H22F3N5O2S
HBD / HBA
2 / 8
Liaisons Rotatives
4
Atomes Lourds
30
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Foire aux questions
A targeted cancer therapy that blocks PI3K-alpha, a specific enzyme that is often overactive due to PIK3CA gene mutations and drives the growth of certain breast, colorectal, and bladder cancers. By interrupting this signaling pathway, alpelisib can slow tumor growth, particularly in hormone receptor-positive, HER2-negative breast cancer.
Targets the HER2 (ErbB2) receptor tyrosine kinase, blocking HER2-mediated signaling that drives proliferation in HER2-overexpressing cancer cells.
Yes, Alpelisib is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL2396661. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 56649450. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="alpelisib"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/alpelisib/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/alpelisib/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/alpelisib/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="alpelisib"></drugfyi-drug>